Skip to main content
Craig Hofmeister, MD, Oncology, Atlanta, GA, Emory University Hospital

CraigCHofmeisterMD

Oncology Atlanta, GA

Hematologic Oncology

Associate Professor, Winship Cancer Institute, Emory University

Dr. Hofmeister is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Hofmeister's full profile

Already have an account?

  • Office

    1365 Clifton Rd
    Rm 4122, 4th floor, Emory Clinic Building B
    Atlanta, GA 30322
    Phone+1 404-778-1900
    Fax+1 404-778-1215
  • Is this information wrong?

Summary

  • I am a hematologist specializing in patients with multiple myeloma.

Education & Training

  • Ohio State University
    Ohio State UniversityMPH, Clinical Investigation, 2009 - 2012
  • Loyola University Medical Center
    Loyola University Medical CenterFellowship, Hematopoietic Stem Cell Transplantation, 2005 - 2006
  • Loyola University Medical Center
    Loyola University Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
  • Loyola University Medical Center
    Loyola University Medical CenterResidency, Internal Medicine, 1999 - 2002
  • Ohio State University College of Medicine
    Ohio State University College of MedicineClass of 1999
  • Brown University
    Brown UniversityBS, Biochemistry and Molecular Biology, 1991 - 1995

Certifications & Licensure

  • LA State Medical License
    LA State Medical License 2020 - 2022
  • AL State Medical License
    AL State Medical License 2020 - 2020
  • NC State Medical License
    NC State Medical License 2020 - 2022
  • GA State Medical License
    GA State Medical License 2017 - 2023
  • OH State Medical License
    OH State Medical License 2006 - 2018
  • IL State Medical License
    IL State Medical License 1999 - 2008
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • Business First’s Forty Under 40 Award Columbus Dispatch, 2011
  • Early Career Achievement Award The Ohio State University College of Medicine, 2011
  • Imagine MMORE Award MMORE (Multiple Myeloma Opportunities for Research & Education), 2009
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma  
    Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology
  • Evidence Does Not Support Clinically Significant Lenalidomide-CCI-779 Interaction via P-Glycoprotein Reply  
    Hofmeister,CC; Yang,X; Phelps,MA, Journal of Clinical Oncology, 1/1/2012
  • Evaluation of pulmonary infiltrates in post stem cell transplant patients  
    Scaglione S, Hofmeister CC, Stiff PJ, Hematology, 12/1/2005
  • Join now to see all

Abstracts/Posters

  • Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...
    Craig C Hofmeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with ...
    Craig C Hofmeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma
    Craig C Hofmeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma
    Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple MyelomaJanuary 9th, 2020
  • Researchers Provide Highlights on Study into Benefits of Reolysin, Kyprolis Combo in Multiple Myeloma
    Researchers Provide Highlights on Study into Benefits of Reolysin, Kyprolis Combo in Multiple MyelomaJanuary 31st, 2020
  • Patients with Low-Risk Myeloma Could Prove Ideal for Daratumumab Therapy
    Patients with Low-Risk Myeloma Could Prove Ideal for Daratumumab TherapySeptember 26th, 2019
  • Join now to see all

Professional Memberships

Hospital Affiliations